In a population-level survey of 2490 patients across 19 cancer types, in which tumor tissue microarrays were used to assess AKR1C3 overexpression, the highest frequency was noted in hepatocellular carcinoma, followed by bladder, breast, prostate, renal, gastric, cervical, colon, and non-small cell lung (NSCLC) cancers [4]. This evidence concerns the gene AKR1C3 and hepatocellular carcinoma.